Cited by 254Atrial Fibrillation Management and OutcomesCardiac Health and Mental HealthHeart Failure Treatment and Management

The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification

Open access
Wynn, G. J., Todd, D. M., Webber, M., Bonnett, L., McShane, J., Kirchhof, P., Gupta, D.·2014·Europace

Abstract

AIMS: To validate the European Heart Rhythm Association (EHRA) symptom classification in atrial fibrillation (AF) and test whether its discriminative ability could be improved by a simple modification. METHODS AND RESULTS: We compared the EHRA classification with three quality of life (QoL) measures: the AF-specific Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire; two components of the EQ-5D instrument, a health-related utility which can be used to calculate cost-effectiveness, and the visual analogue scale (VAS) which demonstrates patients' own assessment of health status. We then proposed a simple modification [modified EHRA (mEHRA)] to improve discrimination at the point where major treatment decisions are made. quality of life data and clinician-allocated EHRA class were prospectively collected on 362 patients with AF. A step-wise, negative association was seen between the EHRA class and both the AFEQT and the VAS scores. Health-related utility was only significantly different between Classes 2 and 3 (P < 0.001). We developed and validated the mEHRA score separating Class 2 (symptomatic AF not limiting daily activities), based on whether the patients were 'troubled by their AF' (Class 2b) or not (Class 2a). This produced two distinct groups with lower AFEQT and VAS scores and, importantly, both clinically and statistically significant lower health utility (Δutility 0.9, P = 0.01) in Class 2b than Class 2a. CONCLUSION: Based on patients' own assessment of their health status and the disease-specific AFEQT, the EHRA score can be considered a useful semi-quantitative classification. The mEHRA score has a clearer separation in health utility to assess the cost efficacy of interventions such as ablation, where Class 2b symptoms appear to be the appropriate treatment threshold.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/europace/eut395

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wynn, G. J., Todd, D. M., Webber, M., Bonnett, L., McShane, J., Kirchhof, P., & Gupta, D.
Affiliations
  • Liverpool Heart and Chest Hospital (GB)
  • University of Liverpool (GB)
  • University of Münster (DE)
Corresponding author
Wynn, G. J.
Venue
Europace
Published
2014-02-16
Volume
16
Issue
7
Pages
965-972
ISSN
  • 1099-5129 (ISSN-L)
  • 1532-2092
OpenAlex
W2130595973
Cited by
254
References
29
Citations by year
2026: 16 · 2025: 22 · 2024: 43 · 2023: 34 · 2022: 36 · 2021: 26 · 2020: 21 · 2019: 11 · 2018: 8 · 2017: 19 · 2016: 8 · 2015: 6 · 2014: 4
FWCI
8.39
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • EP Europace (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
atrial fibrillation, symptom classification, quality of life, visual analogue scale, cost-effectiveness, patient-reported health status
MeSH terms
Aged, Atrial Fibrillation, Cost-Benefit Analysis, Female, Health Resources, Health Status, Health Status Indicators, Humans, Male, Middle Aged, Predictive Value of Tests, Prognosis, Prospective Studies, Quality of Life, Surveys and Questionnaires, Retrospective Studies, Reproducibility of Results, Discriminant Analysis, Health Care Costs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review